Novo Nordisk A/S
NVO
$65.16
$2.544.06%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 0.28% | 39.06% | -21.80% | 16.68% | -3.41% |
| Total Depreciation and Amortization | -96.35% | -30.18% | 6.95% | 348.71% | -74.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -157.76% | 43.94% | 450.00% | -111.18% | -156.68% |
| Change in Net Operating Assets | 91.55% | -226.39% | 201.88% | 17.47% | -191.64% |
| Cash from Operations | -72.79% | -11.33% | 249.63% | 51.16% | -76.95% |
| Capital Expenditure | -28.85% | -18.21% | -22.44% | 9.14% | -59.56% |
| Sale of Property, Plant, and Equipment | -196.95% | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 170.44% | 6.47% | -176.48% | 336.10% | 29.21% |
| Cash from Investing | -323.20% | -2.98% | -619.30% | 127.11% | -9.85% |
| Total Debt Issued | 37,512.61% | -99.66% | -- | -- | -- |
| Total Debt Repaid | 18.61% | 89.47% | -1,494.01% | 10.70% | -36.02% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -211.48% | 67.71% | -162.66% | 70.95% | -58.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 100.00% | -- | 100.00% | -- | 100.00% |
| Other Financing Activities | -- | -- | -200.00% | -- | -- |
| Cash from Financing | 294.14% | -212.64% | 162.66% | -163.04% | 49.58% |
| Foreign Exchange rate Adjustments | 299.82% | -946.18% | -5.41% | 121.23% | -149.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,055.82% | -90.78% | 671.11% | 47.47% | -284.30% |